Butterfly Network Stock Price and Value Analysis

Butterfly Network (NYSE:BFLY) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Butterfly Network to reach your target.

Target type

BFLY Free Cash Flow Trend

Free Cash Flow trendline for BFLY
Free Cash Flow trendline for Butterfly Network

Hmm, we can't give any reliable projection for Butterfly Network's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

AdvantagesDisadvantagesNeutral
None.
  • This stock looks overpriced.
  • This company is less known than others.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

Inside the BFLY Numbers

BFLY Price
(Butterfly Network stock price per share)
$5.40
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Medical Devices stocks
[?] Free Cash Flow Jitter 44%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 34,272,659 shares shorted. With 224,133,100 shares available for purchase and an average trading volume over the past 10 trading days of 4,354,800, it would take at least 7.9 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Net income was negative in all 7 fiscal years from 2019 to 2025, so no ratio of operating cash flow to net income is shown. Operating cash flow totaled -$714 million over those years, against net income of -$747 million.

In 2025, net income was -$77.1 million and operating cash flow was -$12.7 million, so no ratio is shown for that year.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2019 -99.7 -120 4.5 n/a
2020 -163 -81.7 2.4 n/a
2021 -32.4 -189 7.9 n/a
2022 -169 -169 18.3 n/a
2023 -134 -98.8 5.8 n/a
2024 -72.5 -41.7 2.7 n/a
2025 -77.1 -12.7 3.3 n/a

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $27.6 million in 2019 and $97.6 million in 2025, a compound annual growth rate of 23.4% over 6 years.

Revenue rose 19.0% from 2024 to 2025.

Our estimated free cash flow was -$20.3 million in 2025, a negative margin of 20.8% of revenue, meaning the estimate was below zero. In 2019 the estimated margin was negative 452.8%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2019 27.6 -125 -452.8%
2020 46.3 -85.1 -184.0%
2021 62.6 -194 -310.2%
2022 73.4 -177 -241.7%
2023 65.9 -107 -161.7%
2024 82.1 -49.1 -59.9%
2025 97.6 -20.3 -20.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $150 million against total liabilities of $101 million, or 149.7% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 33.9% of total assets in 2025, compared with 345.9% in 2020, a decrease of 312.0 percentage points.

Stockholders equity was $196 million in 2025, up from negative equity of -$362 million in 2020.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was -25.1% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2020 147 60.2 509 -362
2021 572 423 124 448
2022 418 163 92.2 325
2023 304 134 84.2 220
2024 256 88.8 87.2 169
2025 297 150 101 196

Price Versus Our Estimated Value

Free cash flow was negative in every one of the 7 fiscal years we have for Butterfly Network under its current filer.

Year-to-year variability in free cash flow is volatile, measured at 44%.

We do not estimate a fair value for Butterfly Network while its free cash flow growth is not positive, so there is no value comparison here.

No dividend yield is recorded for Butterfly Network in our data.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 100% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Butterfly Network, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Butterfly Network (BFLY) 1,444 - - - -
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
InfuSystem Holdings (INFU) 287 32.6 - - 402% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1804176.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 7 of the 7 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • We have no value estimate for this stock, so no price comparison is made.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: BFLY annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in BFLY

Does Butterfly Network have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: BFLY

This example shows how we apply the Trendshare checklist to BFLY: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 5.40
    • Market cap: $1.4B
    • EPS: -0.21
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.